Low-dose radiation trial finds fewer knee replacements in an early-disease subgroup
A clinical trial presented at the Boston radiation oncology meeting linked a low radiation dose to longer pain relief and less joint deterioration in nonadvanced knee osteoarthritis. In a grade two subgroup, knee replacements occurred in 14% of those given radiation plus medicines, compared with 36% on medicines alone. The subgroup finding remains exploratory; the study lacked simulated radiation and a larger controlled trial is needed.
Science··Morning
Early knee disease met a low radiation dose
A clinical trial presented at the Boston radiation oncology meeting compared medicines alone with the same medicines plus low-dose radiation for people with nonadvanced knee osteoarthritis. The participants received glucosamine and chondroitin; the radiation group also received a total of 4.5 gray across ten sessions. The two groups both reported less pain soon after treatment, but relief lasted longer in the radiation group. The specialist report from AuntMinnie independently describes the same presentation and its central finding of fewer later knee replacements in a subgroup, while the meeting release supplies the trial details.[1], [2]
Joint imaging and disability favored the radiation group
Follow-up magnetic resonance scans showed less deterioration inside the joint over three years. In the first year the imaging score improved slightly with radiation and worsened with medicines alone. Regional health records extended the view to a median of nearly twelve years and showed a lower adjusted hazard of officially certified knee disability in the radiation group. These outcomes speak to more than short-term pain relief, but they come from one trial in one health-care setting. The meeting analysis has not been published in a journal.[1]
The replacement difference came from a small subgroup
In a grade two subgroup, knee replacement occurred in 14 percent of those assigned radiation and 36 percent of those taking medicines alone. The subgroup analysis was exploratory; across all participants, the replacement difference did not meet the statistical significance threshold. Participants also knew which treatment they received, because the comparison arm did not receive simulated radiation. Incomplete imaging follow-up and the inability to assess rare late radiation effects add further limits. A larger sham-controlled trial would test whether the apparent long-term advantage holds beyond this group.[1]
